Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metronidazole.

W D Hager1, R P Rapp

  • 1Department of Obstetrics and Gynecology, University of Kentucky School of Medicine, Lexington.

Obstetrics and Gynecology Clinics of North America
|September 1, 1992
PubMed
Summary
This summary is machine-generated.

Metronidazole is an affordable antibiotic effective for treating bacterial vaginosis and Trichomonas vaginalis infections. It also serves as a cost-effective option for Clostridium difficile-induced colitis and certain resistant anaerobic infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Femoral bone mineral density in patients with heart failure.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2006
Same author

Emerging bacterial pathogens: a consensus of the scientific data and the risk for development of multiple organ dysfunction syndrome.

Surgical infections·2003
Same author

Overview of resistant gram-positive pathogens in the surgical patient.

Surgical infections·2003
Same author

Roundtable discussion of antibiotic therapy in surgical infections.

Surgical infections·2003
Same author

Pharmacokinetics of fluconazole in trauma patients with postpyloric feeding tubes.

The Annals of pharmacotherapy·2001
Same author

Antimicrobial cycling to control bacterial resistance.

The Annals of pharmacotherapy·2001
Same journal

Bridging Science and Practice in Gender-Affirming Care: A Compendium for Gynecologists.

Obstetrics and gynecology clinics of North America·2026
Same journal

Evidence, Clinical Expertise, and Research Gaps in Gender-Affirming Care.

Obstetrics and gynecology clinics of North America·2026
Same journal

Evaluation and Management of the Pediatric Gender-Diverse Patient.

Obstetrics and gynecology clinics of North America·2026
Same journal

Expanding Access to Cervical Cancer Screening for Transgender and Nonbinary Individuals.

Obstetrics and gynecology clinics of North America·2026
Same journal

Updates on Breast Cancer Screening and Special Considerations for Transgender Men and Women.

Obstetrics and gynecology clinics of North America·2026
Same journal

Contraceptive Needs of the Transmasculine Patient.

Obstetrics and gynecology clinics of North America·2026
See all related articles

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Metronidazole is a widely used antibiotic with established efficacy.
  • Limited therapeutic alternatives exist for specific infections like T. vaginalis and bacterial vaginosis.
  • Cost-effectiveness remains a significant factor in antibiotic selection.

Purpose of the Study:

  • To review the established and potential roles of metronidazole in treating various infections.
  • To evaluate metronidazole's utility in cases of antibiotic resistance.
  • To assess metronidazole's position in current treatment guidelines.

Main Methods:

  • Literature review of clinical studies and treatment guidelines.
  • Analysis of metronidazole's efficacy and safety profiles.

Related Experiment Videos

  • Comparison of metronidazole with alternative therapeutic agents.

    • Main Results:

    • Metronidazole is a primary treatment for T. vaginalis and bacterial vaginosis due to efficacy and low cost.
    • It is an inexpensive alternative for C. difficile-induced pseudomembranous colitis.
    • Considered for moderate to severe anaerobic pelvic infections secondary to treatment failure or resistance to other agents.

    Conclusions:

    • Metronidazole remains a crucial antibiotic for specific gynecological and gastrointestinal infections.
    • Its role in treating resistant anaerobic infections and as a cost-effective option is significant.
    • Metronidazole is not recommended as a first-line prophylactic agent in obstetric and gynecologic settings.